Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
Study found adding immunotherapy to radiotherapy significantly improved OS after definitive surgery for primary tumor in patients with brain metastasis.
Immunotherapy improved median overall survival by 7.5 months regardless of what other treatments patients received.
New data show that complete metastasectomy for selected cases of metastatic renal cell carcinoma (mRCC) prolongs survival in the postcytokine therapy era.
A study showed that mortality risk was reduced by 59% for patients who underwent complete metastasectomy compared with those who did not.